Increased respiratory symptoms in COPD patients on withdrawal of therapy: evidence of long-term efficacy gains with formoterol turbuhaler Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002
Evaluation of respiratory muscles‘ function in COPD patients treated with tiotropium Source: Eur Respir J 2005; 26: Suppl. 49, 291s Year: 2005
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014
Nebulized formoterol improves airway function in COPD subjects receiving maintenance tiotropium Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Tiotropium reduces oral prednisone requirements while improving respiratory function in patients with severe persistent asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
The combination therapy with inhaled tiotropium bromide and transdermal tulobuterol in COPD improves the peripheral airway function Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Effect of inhaled tiotropium on tracheobronchial clearance in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
Comparison of spirometric efficacy of fluticasone/salmeterol plus tiotropium and tiotropium alone in moderate COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
As-needed formoterol has an improved safety profile compared with as-needed terbutaline in mild intermittent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Rational timing of combination therapy with tiotropium and formoterol in moderate-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006
Comparison of fluticasone propionate and budesonide on phagocytosis of common respiratory pathogens in COPD patients Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD Source: International Congress 2018 – Advances in exercise physiopathology Year: 2018